FDA pours cold water on PTC Therapeutics' Duchenne application


PTC Therapeutics Inc has not supplied persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, a preliminary review by scientists at the U.S. Food and Drug Administration concluded. The review, posted on the FDA's website on Tuesday, said data to establish the effectiveness of the drug, ataluren, "are not persuasive."



from Biotech News